Cytokinetics INC Form 4 insider transactions

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold shares on January 7, 2025.

Cytokinetics director John T. Henderson acquired 434 shares of common stock through the company's stock retainer program.

Robert Arthur Harrington, a director at Cytokinetics Inc, acquired 255 shares of common stock on January 2, 2025, in lieu of a cash retainer.

Director Edward M. Kaye acquired 255 shares of Cytokinetics Inc. common stock at $48.93 per share on January 2, 2025, through the Director Stock in Lieu of Cash Retainer Program.

Director Nancy Wysenski acquired 127 shares of Cytokinetics Inc. common stock through the Director Stock in Lieu of Cash Retainer Program.

Director Wendell Wierenga acquired 127 shares of Cytokinetics Inc. common stock on January 2, 2025, in lieu of a cash retainer.

A Cytokinetics director, Wendall Wierenga, exercised stock options and sold a portion of the acquired shares on December 16, 2024.

John T. Henderson, an insider at Cytokinetics Inc., engaged in multiple stock transactions on December 11, 2024, including acquisitions and sales of common stock and stock options.

Cytokinetics' EVP of Research and Development, Malik Fady Ibraham, exercised stock options and sold shares on December 10, 2024.

Cytokinetics Inc.'s VP, Chief Accounting Officer, Robert Wong, reported the acquisition and disposal of company stock related to performance stock unit vesting.

Cytokinetics' EVP and Chief Financial Officer, Sung Lee, reported the acquisition and disposal of company stock following the vesting of Performance Stock Units.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, reports the acquisition and disposal of company stock related to vesting performance stock units.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported the acquisition and disposal of company stock following the vesting of Performance Stock Units.

Cytokinetics CEO Robert Blum acquired and disposed of shares following the vesting of Performance Stock Units, resulting in a net change in his holdings.

Cytokinetics CEO Robert I. Blum exercised stock options and sold shares on December 2, 2024.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold shares on November 26, 2024.

Wendall Wierenga, a director at Cytokinetics, exercised stock options and sold a portion of the acquired shares on November 25, 2024.

Cytokinetics CEO Robert I. Blum exercised stock options and sold shares on November 18, 2024.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and sold shares on November 12, 2024.

Cytokinetics' CEO Robert Blum exercised stock options and sold 5,000 shares of common stock on November 1, 2024, according to a recent SEC filing.

Wendall Wierenga, a director at Cytokinetics Inc, exercised stock options and sold shares on October 28, 2024, according to a Form 4 filing with the SEC.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on October 30, 2024, according to a Form 4 filing.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on October 15, 2024.

Cytokinetics' CEO Robert Blum exercised stock options and sold a portion of the acquired shares on October 9, 2024.

Director Robert Arthur Harrington acquired 237 shares of Cytokinetics Inc. common stock on October 1, 2024, in lieu of a cash retainer payment.

Director John T. Henderson reports acquiring 403 shares of Cytokinetics Inc. common stock and disposing of 83 shares held indirectly through a spouse.

Edward M. Kaye, a director at Cytokinetics Inc, acquired 237 shares of common stock on October 1, 2024, in lieu of a cash retainer payment.

Director Wendell Wierenga acquired 118 shares of Cytokinetics Inc. common stock in lieu of a cash retainer payment on October 1, 2024.

Director Nancy Wysenski acquired 118 shares of Cytokinetics Inc. common stock on October 1, 2024, in lieu of a cash retainer payment.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition and disposal of company stock and stock options on October 1, 2024.